Stocktoria

QuidelOrtho Corp QDEL

Nasdaq · stock · In Vitro & In Vivo Diagnostic Substances · website · IPO 1991-02-01 · LEI

QuidelOrtho Corp (QDEL) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $2.7B at a -41.5% net margin.

Chart by TradingView
30/100
Stocktoria Quality Score · grade D
5/9
Piotroski F — financial health
-0.56
Altman Z″ — distress risk · distress
Dividend yield · no dividend

Quality score trend · recomputed for each fiscal year

Piotroski F /9
3 4 3 5 2023202320242025
Altman Z″
3.19 2.78 -0.85 -0.56 2023202320242025

Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.

$14.83 as of 2026-08-01 · -48.3% 1y
$12.30$29.4552-wk
Market cap USD$940M
Net margin 5y avg-11.4%
Return on equity 5y avg-16.1%
Beta0.76
Employees6,500

Analyst price target

$18.62 +25.6% vs last
· 4 analysts
target range $11.00 – $38.00

Wall Street analyst consensus — a sentiment gauge, not our scoring.

Revenue trend · last 5y · up

How it ranks in Manufacturing · percentile among 1957 companies

Piotroski Fstronger than 63%
Net marginstronger than 29%
Return on equitystronger than 26%
Revenue growthstronger than 29%

Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.

Piotroski F breakdown · 5/9 tests passed

Altman Z″ components · distress zone

ComponentValue
Working capital / assets0.083
Retained earnings / assets-0.173
EBIT / assets-0.159
Equity / liabilities0.499

Sector peers · similar-size Manufacturing companies compare side by side →

TickerCompanyPiotroski FAltman Z″P / ERevenue growth
QDELQuidelOrtho Corp5/9-0.56-1.9%
LNTHLantheus Holdings, Inc.4/94.6130.6+0.5%
IDXXIDEXX LABORATORIES INC /DE8/910.4341.1+10.4%
NEOGNEOGEN CORP4/9-0.23-2.7%
MYGNMYRIAD GENETICS INC5/9-5.88-1.6%
NTLAIntellia Therapeutics, Inc.2/9-6.12+16.9%
TKNOAlpha Teknova, Inc.5/9-1.59+7.4%

All Manufacturing companies →

About QuidelOrtho Corp

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California.

FAQ

Is QDEL financially healthy?

QuidelOrtho Corp's Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.

Does QDEL pay a dividend?

No, QuidelOrtho Corp does not currently pay a dividend.

How profitable is QDEL?

In FY2025, QuidelOrtho Corp had a net margin of -41.5% and a return on equity of -58.9%.

What is the analyst price target for QDEL?

The average Wall-Street price target for QuidelOrtho Corp is $18.62, about 25.6% above the recent price, from 4 analysts.

Is QDEL a good stock to buy?

Stocktoria doesn't give buy or sell advice, but here is the data on QuidelOrtho Corp: a Piotroski F-score of 5/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.

Computed from company filings · US · as of 2025-12-28. Facts plus Stocktoria's own computed scores — not investment advice.